Mycophenolate mofetil

被引:79
作者
Zwerner, Jeffrey [1 ]
Fiorentino, David [1 ]
机构
[1] Stanford Univ, Dept Dermatol, Palo Alto, CA 94304 USA
关键词
Cellcept (TM); dermatology; immunomodulators; immunosuppressive; mycophenolate mofetil;
D O I
10.1111/j.1529-8019.2007.00136.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Mycophenolate mofetil (MMF) is a relatively new systemic immunosuppressive agent whose use is rapidly increasing within the field of dermatologic. Originally used in the 1970s for the treatment of psoriasis, MMF has demonstrated efficacy in multiple types of inflammatory skin diseases. Although the safety data within the dermatologic literature is sparse, MMF's extensive use within the field of organ transplantation has demonstrated a favorable safety profile. MMF's lack of hepatic or renal toxicity is a significant advantage over immunosuppressive medications currently used in dermatology and make MMF an attractive candidate for multidrug regimens. In this review the present authors discuss the pharmacology, mechanisms of action, side effects and current uses of MMF reported within the dermatologic literature. The present authors also provide practical information regarding the use of the MMF culled from the literature as well as from the present authors' own clinical experience with the medication.
引用
收藏
页码:229 / 238
页数:10
相关论文
共 94 条
[71]   An evaluation of the usefulness of mycophenolate mofetil in pemphigus [J].
Powell, AM ;
Albert, S ;
Fares, SA ;
Harman, KE ;
Setterfield, J ;
Bhogal, B ;
Black, MM .
BRITISH JOURNAL OF DERMATOLOGY, 2003, 149 (01) :138-145
[72]   Mycophenolate mofetil in patients with hepatitis C virus infection [J].
Ramos-Casals, M ;
Font, J .
LUPUS, 2005, 14 :S64-S72
[73]  
Reinhard G, 2000, ACTA DERM-VENEREOL, V80, P312
[74]   Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil [J].
Robson, R ;
Cecka, JM ;
Opelz, G ;
Budde, M ;
Sacks, S .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (12) :2954-2960
[75]  
ROOS N, 2007, J PHARM EXP THER
[76]  
Rostaing L, 2000, TRANSPLANTATION, V69, P991
[77]   Mycophenolate mofetil in dermatomyositis: Is it safe? [J].
Rowin, J ;
Amato, AA ;
Deisher, N ;
Cursio, J ;
Meriggioli, MN .
NEUROLOGY, 2006, 66 (08) :1245-1247
[78]   Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients [J].
Sarmiento, JM ;
Dockrell, DH ;
Schwab, TR ;
Munn, SR ;
Paya, CV .
CLINICAL TRANSPLANTATION, 2000, 14 (02) :136-138
[79]   Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil [J].
Schanz, S ;
Ulmer, A ;
Rassner, G ;
Fierlbeck, G .
BRITISH JOURNAL OF DERMATOLOGY, 2002, 147 (01) :174-178
[80]   MYCOPHENOLIC-ACID, AN INHIBITOR OF IMP DEHYDROGENASE THAT IS ALSO AN IMMUNOSUPPRESSIVE AGENT, SUPPRESSES THE CYTOKINE-INDUCED NITRIC-OXIDE PRODUCTION IN MOUSE AND RAT VASCULAR ENDOTHELIAL-CELLS PRODUCTION IN MOUSE AND RAT VASCULAR ENDOTHELIAL-CELLS [J].
SENDA, M ;
DELUSTRO, B ;
EUGUI, E ;
NATSUMEDA, Y .
TRANSPLANTATION, 1995, 60 (10) :1143-1148